Biotech Values

[DewDiligence]

PTRO—...does this imply some conviction by these large shareholders in the ultimate success of the final P3 trial?

Not really. The purchases in question were made via the private placement of convertible preferred shares on 6/22/17 (#msg-132402832) in which the conversion price of $0.9949 was a 23% discount to the previous day’s close. There is no lock-up period, so the preferred shares can be converted into common and sold at any time.